Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Innovating CBT-I for Cancer Survivors: An Optimization Trial
NCT06181643 · View on ClinicalTrials.gov ↗
Study Summary
The overall goal of this project is to conduct a factorial, randomized controlled trial to optimize synchronous, virtual delivery of CBT-I for cancer survivors. The proposed project will yield multiple deliverables to innovate cancer survivorship care, chiefly an optimized, scalable, virtually-delivered intervention that addresses chronic insomnia, one of the most deleterious concerns among the growing demographic of cancer survivors in the U.S. Findings will inform future considerations for delivering CBT-I to cancer survivors.
Conditions Studied
Interventions
- BEHAVIORAL Survivorship Sleep Program with Individual Delivery + No Booster Sessions
- BEHAVIORAL Survivorship Sleep Program with Group Delivery + No Booster Sessions
- BEHAVIORAL Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions
- BEHAVIORAL Survivorship Sleep Program with Group Delivery + 3 Booster Sessions
Study Locations (1)
Massachusetts
- Massachusetts General Hospital — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-09-06 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06181643
The ClinicalTrials.gov registry entry for NCT06181643 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 1,948 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 4 interventions — of which Survivorship Sleep Program with Individual Delivery + No Booster Sessions is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06181643 reports 1 study location spanning 1 distinct geographic area — top geographies include Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06181643 about?
NCT06181643 is a clinical study titled "Innovating CBT-I for Cancer Survivors: An Optimization Trial". The overall goal of this project is to conduct a factorial, randomized controlled trial to optimize synchronous, virtual delivery of CBT-I for cancer survivors. The proposed project will yield multiple deliverables to innovate cancer survivorship care, chiefly an optimized, scalable, virtually-deliv...
What is the current status of trial NCT06181643?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-09-06. Estimated completion is 2026-05-31.
What conditions does trial NCT06181643 study?
This clinical trial studies the following conditions: Insomnia, Cancer Survivorship. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06181643?
The interventions under investigation include: Survivorship Sleep Program with Individual Delivery + No Booster Sessions (BEHAVIORAL), Survivorship Sleep Program with Group Delivery + No Booster Sessions (BEHAVIORAL), Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions (BEHAVIORAL), Survivorship Sleep Program with Group Delivery + 3 Booster Sessions (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06181643?
This trial is sponsored by Massachusetts General Hospital, which has 1,948 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06181643 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.